
Chinese pharmaceutical platform Yaoshibang raises $270m

Chinese B2B pharmaceutical trading platform Yaoshibang has raised $270 million from Guangdong Pearl River Investment, Baidu, Sunshine Insurance, Green Pine Capital Partners, Guangzhou government-backed S Fund, and an undisclosed sovereign wealth fund.
Founded in 2015 by a former executive at Chinese real estate portal Soufang.com, the company distributes medicines from upstream drug manufacturers to pharmacies, clinics, and health centers. As of December...
Latest News
Novo Tellus hits $375m first close on third Indo-Pacific fund
Novo Tellus Capital Partners, an investor in industrial technology assets across the Indo-Pacific region, has reached a first close of approximately USD 375m on its third fund – matching the overall target for the vehicle.
Matrix, HongShan back China's Qihan Biotech
Matrix Partners China and HongShan (formerly Sequioa Capital China) have joined a USD 16m pre-Series B round for Qihan Biotech, a genome editing player active in human and agricultural therapies.
Trifecta closes third India venture debt fund on $214m
Trifecta Capital has closed its third India venture debt fund with about INR 17.8bn (USD 214) in commitments. The initial target was INR 10bn with a greenshoe option of INR 5bn.
ShawKwei commits $34m to US EV battery manufacturer
Asia-focused industrial technology investor ShawKwei & Partners has announced its third investment in a US-based company in three weeks, with a USD 34.3m commitment to battery manufacturer Group14 Technologies.